Active Ingredient(s):Denileukin Deftitox FDA Approved: * February 5, 1999 Pharm Company: *SERAGEN Category:Cancer
Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these.
In 1999, Ontak was approved by the U.S. Food and Drug Administration (F...
* May have multiple approval dates, manufacturers, or labelers.